Enovis (NYSE:ENOV) Stock Rating Upgraded by Wells Fargo & Company

Enovis (NYSE:ENOV) was upgraded by equities research analysts at Wells Fargo & Company to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on ENOV. Needham & Company LLC upped their price target on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Canaccord Genuity Group reduced their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. BTIG Research increased their target price on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Stock Down 1.5%

NYSE ENOV opened at $22.61 on Wednesday. Enovis has a 1-year low of $21.00 and a 1-year high of $40.69. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -1.09 and a beta of 1.46. The stock’s 50 day moving average is $23.42 and its two-hundred day moving average is $27.60. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oliver Engert acquired 1,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders bought 5,000 shares of company stock worth $121,983. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

Several institutional investors have recently modified their holdings of ENOV. River Road Asset Management LLC lifted its holdings in Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after buying an additional 46,289 shares during the period. Corient Private Wealth LLC boosted its stake in Enovis by 540.7% in the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after acquiring an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. grew its holdings in Enovis by 75.8% during the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after acquiring an additional 156,069 shares during the period. XTX Topco Ltd bought a new stake in shares of Enovis during the 4th quarter valued at $561,000. Finally, Susquehanna Portfolio Strategies LLC lifted its stake in shares of Enovis by 249.9% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after purchasing an additional 100,704 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.